These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29371638)

  • 1. Characterization of Nanodiamond-based anti-HIV drug Delivery to the Brain.
    Roy U; Drozd V; Durygin A; Rodriguez J; Barber P; Atluri V; Liu X; Voss TG; Saxena S; Nair M
    Sci Rep; 2018 Jan; 8(1):1603. PubMed ID: 29371638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissue.
    Roy U; Ding H; Pilakka-Kanthikeel S; Raymond AD; Atluri V; Yndart A; Kaftanovskaya EM; Batrakova E; Agudelo M; Nair M
    Int J Nanomedicine; 2015; 10():5819-35. PubMed ID: 26425084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism-independent optimization of combinatorial nanodiamond and unmodified drug delivery using a phenotypically driven platform technology.
    Wang H; Lee DK; Chen KY; Chen JY; Zhang K; Silva A; Ho CM; Ho D
    ACS Nano; 2015 Mar; 9(3):3332-44. PubMed ID: 25689511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advancements in Nanodiamond Mediated Brain Targeted Drug Delivery and Bioimaging of Brain Ailments: A Holistic Review.
    Singh M; Mazumder B
    Pharm Nanotechnol; 2022; 10(1):42-55. PubMed ID: 34951376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adsorption of drugs on nanodiamond: toward development of a drug delivery platform.
    Mochalin VN; Pentecost A; Li XM; Neitzel I; Nelson M; Wei C; He T; Guo F; Gogotsi Y
    Mol Pharm; 2013 Oct; 10(10):3728-35. PubMed ID: 23941665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive evaluation of carboxylated nanodiamond as a topical drug delivery system.
    Lim DG; Kim KH; Kang E; Lim SH; Ricci J; Sung SK; Kwon MT; Jeong SH
    Int J Nanomedicine; 2016; 11():2381-95. PubMed ID: 27307736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanodiamonds coupled with plant bioactive metabolites: a nanotech approach for cancer therapy.
    Gismondi A; Reina G; Orlanducci S; Mizzoni F; Gay S; Terranova ML; Canini A
    Biomaterials; 2015 Jan; 38():22-35. PubMed ID: 25457980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy.
    Neely M; Louie S; Xu J; Anthony P; Thuvamontolrat K; Mordwinkin N; Kovacs A
    J Clin Pharmacol; 2015 Jul; 55(7):798-808. PubMed ID: 25683232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
    Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
    Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier.
    Kuo YC; Lee CL
    Colloids Surf B Biointerfaces; 2012 Feb; 90():75-82. PubMed ID: 22024400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle-mediated targeted delivery of antiretrovirals to the brain.
    Mahajan SD; Law WC; Aalinkeel R; Reynolds J; Nair BB; Yong KT; Roy I; Prasad PN; Schwartz SA
    Methods Enzymol; 2012; 509():41-60. PubMed ID: 22568900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An oral formulation of efavirenz-loaded lactoferrin nanoparticles with improved biodistribution and pharmacokinetic profile.
    Kumar P; Lakshmi YS; Kondapi AK
    HIV Med; 2017 Aug; 18(7):452-462. PubMed ID: 28000390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
    Dhoro M; Zvada S; Ngara B; Nhachi C; Kadzirange G; Chonzi P; Masimirembwa C
    BMC Pharmacol Toxicol; 2015 Mar; 16():4. PubMed ID: 25889207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring an alternative explanation for the second phase of viral decay: Infection of short-lived cells in a drug-limited compartment during HAART.
    Sanche S; Mesplède T; Sheehan NL; Li J; Nekka F
    PLoS One; 2018; 13(7):e0198090. PubMed ID: 30016329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbon nanostructures: The drug and the delivery system for brain disorders.
    Henna TK; Raphey VR; Sankar R; Ameena Shirin VK; Gangadharappa HV; Pramod K
    Int J Pharm; 2020 Sep; 587():119701. PubMed ID: 32736018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs.
    Cunha-Reis C; Machado A; Barreiros L; Araújo F; Nunes R; Seabra V; Ferreira D; Segundo MA; Sarmento B; das Neves J
    J Control Release; 2016 Dec; 243():43-53. PubMed ID: 27664327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The adsorption of tetracycline and vancomycin onto nanodiamond with controlled release.
    Giammarco J; Mochalin VN; Haeckel J; Gogotsi Y
    J Colloid Interface Sci; 2016 Apr; 468():253-261. PubMed ID: 26852349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the In Vivo Pharmacokinetics and In Vitro Dissolution of Branded Versus Generic Efavirenz Formulation in HIV-Infected Patients.
    Gervasoni C; Baldelli S; Cerea M; Cenderello G; Bini T; Vimercati S; Iardino R; Gazzaniga A; DʼArminio Monforte A; Clementi E; Cattaneo D
    Ther Drug Monit; 2016 Jun; 38(3):420-2. PubMed ID: 26727626
    [No Abstract]   [Full Text] [Related]  

  • 19. Efavirenz biotransformation as an up-stream event of mood changes in HIV-infected patients.
    Grilo NM; Correia MJ; Sequeira C; Harjivan SG; Caixas U; Diogo LN; Marques MM; Monteiro EC; Antunes AM; Pereira SA
    Toxicol Lett; 2016 Oct; 260():28-35. PubMed ID: 27543169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an in vitro blood-brain barrier model to study molecular neuropathogenesis and neurovirologic disorders induced by human immunodeficiency virus type 1 infection.
    Mukhtar M; Pomerantz RJ
    J Hum Virol; 2000; 3(6):324-34. PubMed ID: 11100913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.